Single vs. repeated matrix metalloproteinase-13 knockdown with intra-articular short interfering RNA administration in a murine osteoarthritis model
- 26 October 2018
- journal article
- research article
- Published by Taylor & Francis in Connective Tissue Research
- Vol. 60 (4) , 335-343
Abstract
Purpose: Our aims were 1) to estimate the duration of short interfering RNA (siRNA) effect on matrix metalloproteinase-13 (Mmp-13) levels by a single intra-articular injection using a mouse knee osteoarthritis (OA) model and 2) to test whether repeated injections results in any additional suppressive effect on cartilage degradation compared to a single injection. Materials and Methods: OA was induced in 9 weeks old male C57BL/6 mice by destabilization of medial meniscus (DMM). Chemically modified siRNA targeted for Mmp-13 was injected into the knee joint at 1 week post-DMM surgery. Control group of knees received that for non-targeted genes. Synovial tissue was collected to measure Mmp-13 expression levels by quantitative polymerase chain reaction (qPCR) at 2, 3, and 6 weeks after surgery in each group. To test the effect of multiple injections, we created four experiment groups according to the number of injections. Histological assessment of articular cartilage was performed at 8 weeks post-DMM surgery. Results: In the Mmp-13 siRNA-treated group, expression levels of Mmp-13 mRNA were decreased by 40% compared to the control group at 2 weeks after surgery (p = 0.04), before returning to baseline at 3 weeks after surgery. A significant improvement in the histological score was observed in all Mmp-13 siRNA-treated groups compared to the control group (p < 0.05). However, no significant differences were seen between the single and multiple injection group. Conclusions: Our results suggested that the duration of siRNA effect in the knee joint lasts for at least 1 week, and that no further benefit is achieved by multiple injections.Keywords
This publication has 26 references indexed in Scilit:
- MMP13 is a critical target gene during the progression of osteoarthritisArthritis Research & Therapy, 2013
- Matrix metalloproteinase protein expression profiles cannot distinguish between normal and early osteoarthritic synovial fluidBMC Musculoskeletal Disorders, 2012
- Molecular changes in articular cartilage and subchondral bone in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritisBMC Musculoskeletal Disorders, 2011
- Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritisAnnals of the Rheumatic Diseases, 2010
- Matrix metalloproteinase 13–deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte developmentArthritis & Rheumatism, 2009
- Sustained long-term RNA interference in nucleus pulposus cells in vivo mediated by unmodified small interfering RNAEuropean Spine Journal, 2009
- OsteoarthritisJournal of Cellular Physiology, 2007
- Long‐lasting RNAi activity in mammalian neuronsFEBS Letters, 2004
- The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis.Journal of Clinical Investigation, 1996
- Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage.Journal of Clinical Investigation, 1996